Celltrion Obtains Patent Rights for COVID-19 Antibody Treatment Substance
[Asia Economy Reporter Kim Daehyun] Celltrion announced on the 14th that it has obtained a patent for a 'binding molecule with neutralizing activity against SARS-CoV-2.' SARS-CoV-2 is the pathogen that causes the novel coronavirus disease (COVID-19).
Hot Picks Today
"Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Lotte Pays Deposit First, Daewoo Responds: Seongsu District 4 Construction Rights Rematch [Real Estate AtoZ]
- Despite ‘Tank Day’ Controversy, Gwangju Schools Purchased Starbucks Gift Certificates
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
This patent is a substance patent for Celltrion's COVID-19 antibody treatment (CT-P59) under development. Celltrion stated, "We submitted a conditional approval application for CT-P59, which uses the antibody covered by this patent, to the Ministry of Food and Drug Safety on the 29th of last month, and we plan to proceed with global approvals including the United States and Europe," adding, "We plan to file an international patent application (PCT) by March."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
